CA-AKTANA,-INC.
5.3.2024 13:01:34 CET | Business Wire | Press release
Aktana, Inc., the leader in intelligent customer engagement for global life sciences and the medical industry, today announced the availability of “Aktana for MedTech,” a set of tools designed to optimize field representative execution, account coordination and medical education programs with AI-powered insights and guidance.
The solution includes Aktana Copilot Mobile for MedTech, an interactive digital assistant that optimizes the execution of sales and marketing strategies across field commercial teams via mobile devices, delivering true omnichannel performance and impact.
“HCPs have overwhelmingly expressed their desire to leverage multiple digital channels to conduct their own research, interact with colleagues and engage with medical company representatives," said John Vitalie, CEO of Aktana. “However, less than 20% of MedTech companies are using advanced omnichannel capabilities. Those doing so are outpacing the industry in revenue by 2x.”
“Aktana for MedTech takes omnichannel to a completely new level by allowing medical device companies to plan and manage their interactions with HCPs through AI-guided intelligence all the way from pre-launch through to face-to-face meetings in the field to follow-up. At the same time, Aktana Copilot Mobile for MedTech captures real-time field reaction data, improving intelligence in real-time with every HCP interaction,” Vitalie continued.
Aktana for MedTech is comprised of Aktana’s world-class open platform, Field Orchestrator, Omnichannel Orchestrator, Analytics Activator, as well as Copilot Mobile. The tools use real-time, intelligence-driven nudges to field teams to simplify call planning and drive more personalized and coordinated activities, ultimately enhancing the quality of interactions with HCPs. Specifically, Aktana for MedTech:
- Allows medical technology companies to simplify scheduling, manage stock, optimize inventory utilization and streamline procurement processes with AI-powered omnichannel orchestration.
- Predicts product thresholds with AI-driven identification of critical account-level product volume changes, combined with dynamic actionable suggestions, to increase sales and decrease costs.
- Delivers medical education content far more effectively with dynamic actionable suggestions to ensure HCPs are getting the best information at the right time to better serve patients.
Concurring with research regarding physician preferences, Dr. Adil Ajuied, a knee surgeon at Guy's and St Thomas' NHS Foundation Trust and the Fortius Clinic London, says, "Being able to streamline the appointment scheduling process by analyzing my availability, preferences, and historical engagement patterns could ensure that meetings are scheduled at optimal times, minimizing disruptions to my clinical responsibilities, and allowing for more focused discussions."
Aktana for MedTech is CRM-agnostic and can integrate with all data sources. The set of tools is modular and can be deployed individually or combined with any of Aktana’s products. Aktana for MedTech is available immediately.
Connect with Aktana on LinkedIn: www.linkedin.com/company/aktana
Follow @aktana_inc on Twitter: www.twitter.com/aktana_inc
About Aktana
Aktana is the leader in intelligent customer engagement for global life sciences and the medical industry. By ensuring that every customer experience is tailored to individual preferences and needs, we help life science companies strengthen their relationships with healthcare providers to inspire better patient care. Aktana transforms the commercial engagement model to make each interaction more effective with proprietary blended-AI and mobile intelligence. Today, commercial and medical teams from more than 350 brands use Aktana’s next generation-AI complete orchestration to deliver personalized omnichannel engagement at scale. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240305334832/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom